$GMED

5 stories mentioning GMEDUpdated 14d ago

Every FINWIRES story that references GMED, newest first.

Globus Medical Insider Sold Shares Worth $2,019,073, According to a Recent SEC Filing

David D Davidar, Director, on June 05, 2026, sold 25,000 shares in Globus Medical (GMED) for $2,019,073. Following the Form 4 filing with the SEC, Davidar has control over a total of 676,142 Class A common shares of the company, with 510,175 shares held directly and 165,967 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1237831/000119312526263997/xslF345X05/ownership.xml

$GMED

Research44d ago

Research Alert: CFRA Keeps Hold Opinion On Shares Of Globus Medical Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target to $84 from $98, based on 16.9x our 2027 EPS estimate, below GMED's five-year average forward P/E multiple. We raise our 2026 EPS view to $4.72 from $4.39 and our 2027 EPS forecast to $4.98 from $4.78. GMED reported a strong start to 2026, with first-quarter results significantly exceeding expectations on both revenue and earnings. Total revenue grew 27% Y/Y to $759.9M, while adjusted EPS surged 64.7% Y/Y to a record $1.12. The performance was led by robust, double-digit growth in the core Globus business, particularly in U.S. Spine, which has now grown over 10% for three consecutive quarters. However, the positive results were partially offset by the revenue decline in the recently acquired Nevro business as it undergoes strategic restructuring. Management attributed this to structural changes in the sales and marketing organization, but the CFO acknowledged that the performance would probably get a little bit worse before it gets better, highlighting some execution risk in the near term.

$GMED

Wire46d ago

RBC Adjusts Price Target on Globus Medical to $120 From $115 as 'Continuing Momentum Fuels Strong Start', Maintains Outperform Rating

Globus Medical (GMED) has an average rating of overweight and mean price target of $111.50, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $78.80, Change: $-6.27, Percent Change: -7.37%

$GMED

Wire47d ago

Needham Adjusts Price Target on Globus Medical to $117 From $114, Maintains Buy Rating

$GMED

Research47d ago

Research Alert: Gmed Posts Strong Q1 On Strong Sales, Margin Expansion, And Nevro Integration

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:GMED delivered exceptional Q1 2026 results, with adjusted EPS of $1.12 (+64.7% Y/Y), significantly exceeding expectations, while net sales reached $759.9M (+27.0% Y/Y). The base business excluding Nevro grew a solid 13.2% Y/Y to $677.2M, indicating healthy organic growth across the portfolio. The standout performance was attributed to remarkable margin expansion, with adjusted EBITDA margins improving 260 bps to 32.3% and gross margins expanding 280 bps to 66.4% as the company continued realizing meaningful synergies from its NuVasive and Nevro acquisitions. Management raised 2026 adjusted EPS guidance to $4.70-$4.80 from the previous $4.40-$4.50 range while reaffirming revenue guidance of $3.18B-$3.22B, reflecting confidence in operational leverage benefits. The core spine business showed particular strength, with US Spine delivering its third consecutive quarter of over 10% growth, while Nevro integration progressed in line with expectations, contributing $82.7M in sales during the quarter.

$GMED

Track with the FINWIRES app suite

FolioX

Track GMED in your portfolio

WheelAI

Analyze GMED options with the wheel strategy

StockInsider

See market sentiment on GMED